165 related articles for article (PubMed ID: 35297231)
1. Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe.
Ozieranski P; Martinon L; Jachiet PA; Mulinari S
Int J Health Policy Manag; 2022 Dec; 11(12):2842-2859. PubMed ID: 35297231
[TBL] [Abstract][Full Text] [Related]
2. Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review.
Ozieranski P; Martinon L; Jachiet PA; Mulinari S
BMJ Open; 2021 Dec; 11(12):e053138. PubMed ID: 34916317
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries.
Mulinari S; Martinon L; Jachiet PA; Ozieranski P
Health Policy; 2021 Jul; 125(7):915-922. PubMed ID: 34006392
[TBL] [Abstract][Full Text] [Related]
4. International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency.
Ozieranski P; Saito H; Rickard E; Mulinari S; Ozaki A
Global Health; 2023 Mar; 19(1):14. PubMed ID: 36869318
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK.
Rickard E; Ozieranski P; Mulinari S
Health Policy; 2019 Dec; 123(12):1244-1250. PubMed ID: 31455562
[TBL] [Abstract][Full Text] [Related]
6. Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts.
Mulinari S; Ozieranski P
BMJ Open; 2018 Oct; 8(10):e023094. PubMed ID: 30344175
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015.
Ozieranski P; Csanadi M; Rickard E; Tchilingirian J; Mulinari S
JAMA Netw Open; 2019 Jun; 2(6):e196253. PubMed ID: 31225896
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
[TBL] [Abstract][Full Text] [Related]
9. Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study.
Raftery J; Bryant J; Powell J; Kerr C; Hawker S
Health Technol Assess; 2008 Apr; 12(10):1-128, iii. PubMed ID: 18405468
[TBL] [Abstract][Full Text] [Related]
10. Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis.
Rickard E; Carmel E; Ozieranski P
BMJ Open; 2023 Mar; 13(3):e061591. PubMed ID: 36990486
[TBL] [Abstract][Full Text] [Related]
11. Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.
Fabbri A; Santos A; Mezinska S; Mulinari S; Mintzes B
Int J Health Policy Manag; 2018 Jun; 7(6):504-509. PubMed ID: 29935127
[TBL] [Abstract][Full Text] [Related]
12. Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study.
Moriarty F; Larkin J; Fahey T
Health Policy; 2021 Oct; 125(10):1297-1304. PubMed ID: 34429238
[TBL] [Abstract][Full Text] [Related]
13. Drug company payments to General Practices in England: Cross-sectional and social network analysis.
Saghy E; Mulinari S; Ozieranski P
PLoS One; 2021; 16(12):e0261077. PubMed ID: 34874975
[TBL] [Abstract][Full Text] [Related]
14. Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016).
Ozieranski P; Csanádi M; Rickard E; Mulinari S
BMJ Open; 2020 Sep; 10(9):e037351. PubMed ID: 32950962
[TBL] [Abstract][Full Text] [Related]
15. Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016.
Stoll M; Hubenschmid L; Koch C; Lieb K
BMJ Open; 2020 Sep; 10(9):e037395. PubMed ID: 32948560
[TBL] [Abstract][Full Text] [Related]
16. Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
Pashley D; Ozieranski P; Mulinari S
Int J Health Serv; 2022 Jul; 52(3):347-362. PubMed ID: 35230175
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Conflicts of Interest among Published Hernia Researchers Self-Reported with the Centers for Medicare and Medicaid Services Open Payments Database.
Olavarria OA; Holihan JL; Cherla D; Perez CA; Kao LS; Ko TC; Liang MK
J Am Coll Surg; 2017 May; 224(5):800-804. PubMed ID: 28167228
[TBL] [Abstract][Full Text] [Related]
18. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016.
Ozaki A; Saito H; Senoo Y; Sawano T; Shimada Y; Kobashi Y; Yamamoto K; Suzuki Y; Tanimoto T
Health Policy; 2020 Jul; 124(7):727-735. PubMed ID: 32439213
[TBL] [Abstract][Full Text] [Related]
19. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
Kato M; Ishikawa H; Okuhara T; Kiuchi T
Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
[TBL] [Abstract][Full Text] [Related]
20. Industry Payments to Adult Reconstruction-Trained Orthopedic Surgeons: An Analysis of the Open Payments Database From 2014 to 2019.
White PB; Iturriaga C; Frane N; Partan MJ; Ononuju U; Mont MA; Bitterman A
J Arthroplasty; 2021 Nov; 36(11):3788-3795. PubMed ID: 34362596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
